Science and Research

A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical and/or interventional treatment Chronic Thromboembolic Pulmonary Hypertension.

The primary objective of the study is to evaluate the effect of selexipag on PVR versus placebo in subjects with inoperable CTEPH (ie, technically non-operable) and persistent/recurrent CTEPH after surgical (PEA) and/or interventional (BPA) treatment at Week 20.